Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

University of Glasgow

Headquarters: Glasgow, United Kingdom
Year Founded: 1451
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Aug 15, 2024
Management Tracks

CFO Kemula leaving CureVac

Plus: Chemify hires CBO to realize commercial ambitions and more from Biocartis and Estrella
BioCentury | Mar 12, 2024
Discovery & Translation

Distillery spotlight: new mitochondrial mechanisms from academia

Correcting mitochondrial dynamics, metabolic control of pathogenic or therapeutic cells emerge among translational innovations in BioCentury’s survey of 2023 publications
BioCentury | Nov 15, 2023
Finance

Nov. 14 Quick Takes: TPG leads $85M B round for ADC play MBrace

Plus: Nouscom raises €67.5M series C and more from Eyebio, Glox, Bayer and Ketabon
BioCentury | Sep 12, 2023
Distillery Therapeutics

Inhibition of MPC1/2 for TKI-resistant CML

BioCentury | Aug 2, 2023
Distillery Therapeutics

TOP2A-targeting cyanotriazole for trypanosome infections

BioCentury | Aug 2, 2023
Finance

Aug. 2 Quick Takes: CG Oncology raises $105M crossover round

Plus: Emerson Collective spins out Yosemite with $200M cancer fund, first commercial patient receives Sarepta’s DMD gene therapy, and more
BioCentury | Oct 27, 2021
Distillery Therapeutics

Inhibiting ULK1 to sensitize CML to TKIs

BioCentury | Jun 22, 2020
Finance

In a first for the British Business Bank, firm backs Epidarex’s new fund

£102M raise gives trans-Atlantic firm ability to retain larger stakes later in life sciences portfolio companies
Items per page:
1 - 10 of 92